1. Home
  2. Analysis
  3. Carbamazepine
  4. Hepatocellular-damage-aggravated

Carbamazepine and Hepatocellular damage aggravated - a phase IV clinical study of FDA data

Summary:

Hepatocellular damage aggravated is reported as a side effect among people who take Carbamazepine (carbamazepine), especially for people who are female, 50-59 old, have been taking the drug for < 1 month also take Lorazepam, and have Rheumatoid arthritis.

The phase IV clinical study analyzes which people have Hepatocellular damage aggravated when taking Carbamazepine. It is created by eHealthMe based on reports of 43,715 people who have side effects when taking Carbamazepine from the FDA, and is updated regularly.

What is Carbamazepine?

Carbamazepine has active ingredients of carbamazepine. It is often used in epilepsy. eHealthMe is studying from 44,628 Carbamazepine users. Check the latest studies of Carbamazepine.

What is Hepatocellular damage aggravated?

Hepatocellular damage aggravated (serious liver damage) is found to be associated with 503 drugs and 192 conditions by eHealthMe. Check the latest studies of Hepatocellular damage aggravated.

On Aug, 02, 2026

43,715 people reported to have side effects when taking Carbamazepine.
Among them, 45 people (0.1%) have Hepatocellular damage aggravated.

Could Carbamazepine cause Hepatocellular damage aggravated?

Among these 45 people:

How long have people been on Carbamazepine when they have Hepatocellular damage aggravated? *

  • < 1 month: 50 %
  • 1 - 6 months: 50 %
  • 6 - 12 months: 0.0 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

What is the gender of people who have Hepatocellular damage aggravated when taking Carbamazepine? *

  • female: 53.33 %
  • male: 46.67 %

What is the age of people who have Hepatocellular damage aggravated when taking Carbamazepine? *

  • 0-1: 0.0 %
  • 2-9: 5.13 %
  • 10-19: 12.82 %
  • 20-29: 15.38 %
  • 30-39: 12.82 %
  • 40-49: 15.38 %
  • 50-59: 23.08 %
  • 60+: 15.38 %

What are other drugs people take besides Carbamazepine? *

  1. Lorazepam: 8 people, 17.78%
  2. Valproic Acid: 6 people, 13.33%
  3. Vioxx: 5 people, 11.11%
  4. Clonazepam: 5 people, 11.11%
  5. Neurontin: 5 people, 11.11%
  6. Xenical: 4 people, 8.89%
  7. Synthroid: 4 people, 8.89%
  8. Metoclopramide: 4 people, 8.89%
  9. Methotrexate: 4 people, 8.89%
  10. Prednisone: 4 people, 8.89%

What are other side effects people have besides Hepatocellular damage aggravated? *

  1. Fever: 19 people, 42.22%
  2. Hepatic Failure (liver failure): 9 people, 20.00%
  3. Cholestasis (a condition where bile cannot flow from the liver to the duodenum): 5 people, 11.11%
  4. Hepatic Necrosis (large portions of liver die off due to severe liver disease): 5 people, 11.11%
  5. Shock (a life-threatening condition with symptoms like low blood pressure, weakness, shallow breathing, cold, clammy skin): 5 people, 11.11%
  6. Fatigue (feeling of tiredness): 5 people, 11.11%
  7. Drug Hypersensitivity: 5 people, 11.11%
  8. Vision Blurred: 4 people, 8.89%
  9. Headache (pain in head): 4 people, 8.89%
  10. Gallstones (stone formation by bile component): 4 people, 8.89%

What are the existing conditions these people have? *

  1. Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 4 people, 8.89%
  2. Pulmonary Embolism (blockage of the main artery of the lung): 2 people, 4.44%
  3. Pain: 2 people, 4.44%
  4. Oligodendroglioma (a type of glioma that are believed to originate from the oligodendrocytes of the brain or from a glial precursor cell): 2 people, 4.44%
  5. Diabetic Neuropathy (neuropathic disorders that are associated with diabetes mellitus): 2 people, 4.44%
  6. Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body): 2 people, 4.44%
  7. Insomnia (sleeplessness): 1 person, 2.22%
  8. Grand Mal Convulsion (a type of generalized seizure that affects the entire brain): 1 person, 2.22%
  9. Drug Withdrawal Syndrome (interfere with normal social, occupational, or other functioning. are not due to another medical condition, drug use, or discontinuation): 1 person, 2.22%
  10. Drug Dependence: 1 person, 2.22%

* Approximation only. Some reports may have incomplete information.

Do you take Carbamazepine and have Hepatocellular damage aggravated?

- Check whether Hepatocellular damage aggravated is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Carbamazepine:

Hepatocellular damage aggravated treatments and more:

How severe was Hepatocellular damage aggravated and when was it recovered:

Expand to all the drugs that have ingredients of carbamazepine:

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Carbamazepine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hepatocellular damage aggravated:

Browse all the conditions that are associated with Hepatocellular damage aggravated:

Related publications that referenced our studies

How the study uses the data?

The study uses data from the FDA. It is based on carbamazepine (the active ingredients of Carbamazepine) and Carbamazepine (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.